Neutral impactStocks
Mankind Pharma Q2 Review: Export Momentum Continues; Systematix Maintains 'Hold'; Check Target Price
NDTV Profit 1 hr ago·27 Oct 2026, 4:33 am
Mankind Pharma gross profit grew 18.9% YoY, exceeding Systematix' estimate and consensus by 2.4% and 4.9%, respectively.
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Mankind Pharma (MANKIND).
- Category: Stocks.
Why it matters
A routine update for Mankind Pharma. Use the price and stock snapshot to gauge how the market is responding.
